£890.00

It has never been this cheap. We have no record of a lower price.

£890 today · cheaper than every other day in the last 3 months

The 2027-2032 World Outlook for Bone Morphogenetic Proteins

View at Amazon

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 55 days · 55 data points (no recent data)

Historical
Generating forecast…
£890.00 £845.50 £863.30 £881.10 £898.90 £916.70 £934.50 22 August 2026 04 September 2026 18 September 2026 01 October 2026 15 October 2026
View at Amazon ↗

Price data last checked 36 day(s) ago - refreshing...

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↑ Price chart
when this has been cheap or pricey
↑ Forecast
where the price is heading next
↓ Statistics
all-time high & low, recent range
↑ Price alert
name your number, we'll email you

Price Distribution

Price distribution over 55 days • 1 price levels

Days at Price
55 days 0 14 28 41 55 £890 Days at Price

Price Analysis

Most common price: £890 (55 days, 100.0%)

Price range: £890 - £890

Price levels: 1 different prices over 55 days

Description

This study covers the world outlook for bone morphogenetic proteins across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of bone morphogenetic proteins as including all commonly understood products falling within this broad category, such as naturally occurring proteins found in the human body; bone morphogenetic proteins that induce mesenchymal stem cells to differentiate into osteoblast cells; and technologies for treatment in spinal fusions, trauma, and reconstructive surgery, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Biopharm, Cellumed, De Puy, Ember Therapeutics, Medtronic, ProSpec, R&D Systems, Sigma Aldrich, Stryker, and Thermo Fischer Scientific. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2026).

Product Specifications

Format
paperback
Domain
Amazon UK
Release Date
05 January 2026
Listed Since
04 February 2026

Similar Products You Might Like

The 2027-2032 World Outlook for Medical Exoskeletons
95% match

The 2027-2032 World Outlook for Medical Exoskeletons

£890.00 24 Oct 2026
The 2027-2032 World Outlook for Molecular Biology Laboratory Reagents
95% match

The 2027-2032 World Outlook for Molecular Biology Laboratory Reagents

£890.00 21 Sep 2026
The 2027-2032 World Outlook for Biotherapeutics Cell Line Developments
94% match

The 2027-2032 World Outlook for Biotherapeutics Cell Line Developments

£890.00 16 Oct 2026
The 2027-2032 World Outlook for Medical Bionic Implants and Exoskeletons
94% match

The 2027-2032 World Outlook for Medical Bionic Implants and Exoskeletons

£890.00 27 Oct 2026
The 2027-2032 World Outlook for Vital Organs Support Systems and Medical Bionics
94% match

The 2027-2032 World Outlook for Vital Organs Support Systems and Medical Bionics

£890.00 16 Oct 2026
The 2027-2032 World Outlook for Upstream Biopharmaceutical Fermentation Products
94% match

The 2027-2032 World Outlook for Upstream Biopharmaceutical Fermentation Products

£890.00 16 Oct 2026
The 2027-2032 World Outlook for Interventional Radiology Products
94% match

The 2027-2032 World Outlook for Interventional Radiology Products

£890.00 10 Sep 2026
The 2027-2032 World Outlook for Biometrics
94% match

The 2027-2032 World Outlook for Biometrics

£890.00 16 Oct 2026
The 2027-2032 World Outlook for Molecular Sieves
94% match

The 2027-2032 World Outlook for Molecular Sieves

£890.00 22 Oct 2026
The 2027-2032 World Outlook for Butanes
94% match

The 2027-2032 World Outlook for Butanes

£890.00 22 Oct 2026
The 2027-2032 World Outlook for Bloodstream Infection Testing
94% match

The 2027-2032 World Outlook for Bloodstream Infection Testing

£890.00 27 Oct 2026
The 2027-2032 World Outlook for Smart Exoskeletons
94% match

The 2027-2032 World Outlook for Smart Exoskeletons

£890.00 07 Sep 2026
The 2027-2032 World Outlook for Chronic Obstructive Pulmonary Disease Treatments
94% match

The 2027-2032 World Outlook for Chronic Obstructive Pulmonary Disease Treatments

£890.00 16 Oct 2026
The 2027-2032 World Outlook for G-Protein Coupled Receptors
94% match

The 2027-2032 World Outlook for G-Protein Coupled Receptors

£890.00 16 Oct 2026
The 2027-2032 World Outlook for Interventional Radiology Systems
94% match

The 2027-2032 World Outlook for Interventional Radiology Systems

£890.00 08 Sep 2026
The 2027-2032 World Outlook for High-Density Multiplexed Diagnostic Assays
94% match

The 2027-2032 World Outlook for High-Density Multiplexed Diagnostic Assays

£890.00 09 Sep 2026
The 2027-2032 World Outlook for Induced Pluripotent Stem Cell (iPSC)
94% match

The 2027-2032 World Outlook for Induced Pluripotent Stem Cell (iPSC)

£890.00 16 Nov 2026
The 2027-2032 World Outlook for Hydroxychloroquine Sulphates
93% match

The 2027-2032 World Outlook for Hydroxychloroquine Sulphates

£890.00 21 Sep 2026
The 2027-2032 World Outlook for Military Exoskeletons
93% match

The 2027-2032 World Outlook for Military Exoskeletons

£890.00 26 Oct 2026
The 2027-2032 World Outlook for Lipids
93% match

The 2027-2032 World Outlook for Lipids

£890.00 24 Oct 2026
The 2027-2032 World Outlook for Glaucoma Pharmaceuticals
93% match

The 2027-2032 World Outlook for Glaucoma Pharmaceuticals

£890.00 21 Oct 2026
The 2027-2032 World Outlook for Medical Exoskeleton Hardware
93% match

The 2027-2032 World Outlook for Medical Exoskeleton Hardware

£890.00 14 Nov 2026
The 2027-2032 World Outlook for Speciality Fertilizers
93% match

The 2027-2032 World Outlook for Speciality Fertilizers

£890.00 26 Oct 2026
The 2027-2032 World Outlook for Cricket Protein Powders
93% match

The 2027-2032 World Outlook for Cricket Protein Powders

£890.00 17 Nov 2026